Integrated Biopharma (Integrated Biopharma) Change In Working Capital : $-1.47 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Change In Working Capital?

Integrated Biopharma's change in working capital for the quarter that ended in Mar. 2024 was $0.17 Mil.

Integrated Biopharma's change in working capital for the fiscal year that ended in Jun. 2023 was $-0.30 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Integrated Biopharma Change In Working Capital Historical Data

The historical data trend for Integrated Biopharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Change In Working Capital Chart

Integrated Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Working Capital

Get a 7-Day Free Trial

-2.43

-2.11

-3.05

0.51

-0.30

Integrated Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															1.07	-1.64	0.99	-0.99	0.17

Integrated Biopharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Integrated Biopharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma (Integrated Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

http://www.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431